Categories: News

STARMED Unveils New Brand Identity to Drive Global Multi-Modality Strategy

SEOUL, South Korea, Jan. 8, 2026 /PRNewswire/ — STARMED, a pioneer in innovative minimally invasive treatment solutions, has announced a comprehensive rebranding. Now in its seventeenth year of operation, the company is formally transitioning from a Radiofrequency Ablation (RFA) specialist into a global multi-modality medical technology platform.

- Advertisement -

Established in 2009, STARMED pioneered the first thyroid-dedicated RFA electrode, effectively creating a clinical field that did not previously exist. This technology has since been adopted into various international clinical guidelines and continues to maintain the leading global market share today. Building on this heritage, STARMED has expanded its portfolio to address diverse clinical needs in liver, uterine, and vascular care, introducing various products such as the proprietary multi-electrode Octopus system. The current rebranding signals a strategic commitment to expand beyond RFA by integrating diverse energy sources, including Microwave Ablation (MWA) and Irreversible Electroporation (IRE), into a unified therapeutic offering.

- Advertisement -

“With the global thermal ablation market projected to reach $2 billion by 2033, this rebranding is a pivotal step for our next stage of growth,” said CEO Henry Shin.

- Advertisement -

The newly unveiled Corporate Identity reflects both STARMED’s heritage and its future vision. The symbol represents technical precision by visualising the initial ‘S’ alongside the silhouette of an electrode tip. This reflects a dedication to minimising patient pain and providing care throughout the recovery process. The wordmark employs a sophisticated, futuristic typeface to reinforce trust within the global healthcare arena.

- Advertisement -

Supported by strong financial foundations, STARMED plans to capitalise on a market growing at 10.5% annually. The company remains committed to establishing minimally invasive treatments as the global ‘Standard of Care’ through enhanced clinical partnerships.

- Advertisement -

About STARMED

- Advertisement -

STARMED is a medical device specialist founded in 2009. With more than 660 clinical research evidence, the company provides world-class thermal ablation solutions to over 70 countries and continues to advance minimally invasive treatment as the clinical standard.

- Advertisement -

Photo – https://mma.prnewswire.com/media/2857156/STARMED_800px.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/starmed-unveils-new-brand-identity-to-drive-global-multi-modality-strategy-302655927.html

- Advertisement -

Recent Posts

DELIVERING CRICKET AT SCALE: DP WORLD DRIVES ICC MEN’S T20 WORLD CUP 2026 LOGISTICS ACROSS INDIA AND SRI LANKA

Broadcast and match infrastructure moved across five countries to ensure venues and production teams were…

2 hours ago

UK Food & Drink Exporters Set to Expand Trade Opportunities at AAHAR 2026

NEW DELHI, March 11, 2026 /PRNewswire/ -- Following the signature of the landmark UK-India Free…

2 hours ago

Markel appoints Phil Jones as Chief Information Officer, International

LONDON, March 11, 2026 /PRNewswire/ -- Markel Insurance, the insurance operation within Markel Group Inc.…

2 hours ago

Global Momentum Accelerates: GAC’s Overseas Sales More Than Double Year-on-Year in February

GUANGZHOU, China, March 11, 2026 /PRNewswire/ -- Building on a strong start in January, GAC…

2 hours ago

CHF ~65 million investment in 2025: Swiss President Guy Parmelin inaugurates new Toblerone production line in Switzerland

The ~65 million Swiss Francs (CHF) investment announced in 2025 to create the global "Center…

2 hours ago

Commit Biologics appoints serial biotech founder as new CEO to take complement-powered immune engagers into the clinic

Dr. Thomas L. F. Montgomery Andresen joins from T-Cypher BioFollows breakthrough non-human primate data demonstrating…

3 hours ago